Wegovy and Possible Vision Risk - Summary - MDSpire
Clinical Guidelines

Wegovy and Possible Vision Risk

Higher dose weight loss injectable demonstrates nearly five times higher ischaemic optic neuropathy risk than other semaglutide GLP-1 agonists

  • April 8, 2026

  • 3 min

Share

GLP-1 receptor agonists, primarily semaglutide, are crucial in treating type 2 diabetes and obesity. A recent observational study analyzed over 30 million FDA adverse event reports from 2017 to 2024, discovering a significant association between semaglutide and ischemic optic neuropathy (ION), especially with the injectable formulation Wegovy. This raises concerns for prescribing clinicians and highlights the need for further research to explore possible mechanisms for the risk and the implications for specific patient groups. Understanding these ocular effects is vital as GLP-1RAs evolve in metabolic disease management.

Original Source(s)

Wegovy and Possible Vision Risk

  • April 8, 2026

Related Content

The Missing Piece in the Dark Metabolome Puzzle?

Microdroplets formed during electrospray ionization may trigger chemical reactions that help explain a substantial portion of the “dark metabolome” – though some researchers question their relevance under typical metabolomics conditions

FDA Approves First Generic Versions of FARXIGA

Agency approves multiple dapagliflozin generics to reduce heart failure hospitalization risk and improve glycemic control in adults with type 2 diabetes

Deprescribing Seen in T2D Care

Researchers examine medication changes in practices with lifestyle medicine access